ADULT MEDICATION GUIDELINE	
Nystatin	
Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology
This document should be read in conjunction with the Disclaimer.	

Quick Links

Dose	Administration	Monitoring	Pregnancy and Breastfeeding

Restrictions

Formulary: Unrestricted

Medication Class

Polyene antifungal

Presentation

Capsule: 500,000 units

Oral suspension: 100,000 units/mL (24 mL)

Vaginal cream: 100,000 units/ dose (75 g)

Storage

Store at room temperature, below 25°C

Dose

Vulvovaginal candidiasis

Per vagina:

1 applicatorful intravaginally, once daily for 14 days

Candidiasis in pregnancy

Per vagina:

1 applicatorful intravaginally, once daily, for 14 days

Vaginal applicators may be used with care in pregnancy

Recurrent candidiasis

Per vagina:

1 applicatorful intravaginally weekly at night, followed by 1-2 times weekly use

Oropharyngeal candidiasis

Oral:

1 mL (100,000 units) 4 times daily for 7 to 14 days. Continue to use for several days after symptoms disappear. Higher doses, e.g. 500,000 units 4 times daily, can be used.

Administration

Oral Liquid

Swirl around mouth for as long as comfortable then swallow. Use after meals/drinks and just before bed.

Vaginal Cream

To be inserted high in the vagina using the applicator provided. Use with care in pregnancy.

Vaginal creams are best used at bedtime

Pregnancy

1st Trimester: Safe to use

2nd Trimester: Safe to use

3rd Trimester: Safe to use

Breastfeeding

Safe to use

Comments

Do not use contraceptive diaphragms or condoms during therapy as they may be damaged by nystatin vaginal cream

Clean the applicator after each use

Therapy should be continued during menstruation; use sanitary pads instead of tampons

Extended treatment duration (12-14 days) is required in pregnancy due to lower response rates and more frequent relapse

Related Policies, Procedures & Guidelines

WNHS Policies:

Antimicrobial Stewardship (AMS) policy

WNHS Clinical Practice Guidelines:

Vaginal infections: Antibiotic treatment for

References

Australian Medicines Handbook. Nystatin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2026 [cited 2026 Jan 15]. Available from: https://amhonline.amh.net.au/

Australian Medicines Handbook. Vulvovaginal candidiasis. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2026 [cited 2026 Jan 15]. Available from: https://amhonline.amh.net.au/

The Royal Women's Hospital. Nystatin. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2025 [cited 2026 Jan 15]. Available from: https://thewomenspbmg.org.au/

Therapeutic Guidelines. Vulvovaginitis caused by Candida and related species in adults. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2025 [cited 2026 Jan 15]. Available from: https://tgldcdp.tg.org.au

MIMS Australia. Nystatin Vaginal. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 [cited 2021 May 25]. Available from: https://www.mimsonline.com.au

AusDI [Internet]. St Leonards (NSW): Health Communication Network; c2021. Nystatin Vaginal Cream; [updated 2018 Feb 18; cited 2026 Jan 15]. Available from: https://ausdi-hcn-com-au.kelibresources.health.wa.gov.au/productMonograph.hcn?file=0278

Australian STI Management Guidelines for Use in Primary Care. Candidiasis. The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine; 2024 [cited 2026 Jan 15]. Available from: https://sti.guidelines.org.au/sexually-transmissible-infections/candidiasis/

Keywords	Nystatin, candidiasis, thrush, nilstat, vaginal thrush				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	3.0 Updated links and references, 14-day treatment for vulvovaginal candidiasis				
Date First Issued:	31/07/2015	Last Reviewed:	27/01/2026	Review Date:	27/01/2031
Endorsed by:	Medicines and Therapeutics Committee			Date:	03/02/2026
NSQHS Standards Applicable:	☒ Std 1: Clinical Governance ☐ Std 2: Partnering with Consumers ☒ Std 3: Preventing and Controlling Healthcare Associated Infection ☒ Std 4: Medication Safety			☐ Std 5: Comprehensive Care ☐ Std 6: Communicating for Safety ☐ Std 7: Blood Management ☐ Std 8: Recognising and Responding to Acute Deterioration	
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2026

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.